• Explore /
  • Poster
  • / Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.

Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.

Abstract Poster

Authors

null

Arthur Daban

APHP, PARIS, France

Arthur Daban , Cecile Gonnin , Yann-Alexandre Vano , Letuan Phan , Agnes lillo-Lelouet , Christine le Beller , Jacques Pouchot , Elizabeth Fabre , Laurence Weiss , Eric Tartour , Stephane Oudard , Marie-Agnès Dragon Durey , Audrey Simonaggio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2523)

DOI

10.1200/JCO.2022.40.16_suppl.2523

Abstract #

2523

Poster Bd #

179

Abstract Disclosures

Similar Posters

First Author: Hassan Mohammed Abushukair

First Author: Jifang Gong

First Author: Mario Machado Lopes

First Author: Matthaios Kapiris